Developer gets OK to expand first-in-human trial of ALS therapy to Europe
WHY IT MATTERS
ALS patients in the U.K. and EU now have access to a first-in-human trial for a novel therapy, potentially expanding treatment options beyond currently available medications for this rapidly progressive disease.
A company called Vectory Therapeutics has received permission to test its experimental ALS drug, called VTx-002, at hospitals in the United Kingdom and European Union. The drug is already being tested in the United States as part of a Phase 1/2 clinical trial. This expansion means more patients in Europe may have the opportunity to participate in this early-stage study of a potential new ALS treatment.
Vectory Therapeutics has been given a green light to expand its first-in-human clinical trial of VTx-002, its treatment candidate for amyotrophic lateral sclerosis (ALS), to sites in the U.K. and the European Union. The Phase 1/2 PIONEER-ALS study (NCT07287397) is already underway in the U.S., and is still enrolling adults with the progressive disease at […] The post Developer gets OK to expand first-in-human trial of ALS therapy to Europe appeared first on ALS News Today .
ASK YOUR DOCTOR
If you have ALS and live in the U.K. or EU, ask your neurologist whether you might be eligible for the PIONEER-ALS trial (NCT07287397) or request a referral to a participating site.